topiramate

Topiramate (RWJ 17021) is a unique antiseizure medication that is used in the treatment of partial and generalized seizures. Topiramate has been rarely associated with hepatic injury and largely when used in combination with other anticonvulsant medications.

Topiramate D12 is a deuterium labeled Topiramate. Topiramate is an agent of broad-spectrum antiepileptic. Topiramate is an antagonist of GluR5 receptor.

Topiramate lithium (McN 4853) is a broad-spectrum antiepileptic compound with GluR5 receptor antagonistic properties. Its mechanism of action includes enhancing GABAergic activity, inhibiting kainate/AMPA receptors, voltage-sensitive sodium and calcium channels, and increasing potassium conductance. Additionally, this compound inhibits carbonic anhydrase. [1][2][3]

Topiramate-13C6 (McN 4853-13C6) is the 13C labeled form of Topiramate. Topiramate (McN 4853) serves as a broad-spectrum antiepileptic agent. It functions as a GluR5 receptor antagonist and exhibits anticonvulsant effects by enhancing GABAergic activity, inhibiting kainate/AMPA receptors, blocking voltage-sensitive sodium and calcium channels, increasing potassium conductance, and inhibiting carbonic anhydrase.

Topiramate (Standard) is a reference standard for research and analysis in studies involving Topiramate. Topiramate (RWJ 17021) is a unique antiseizure medication that is used in the treatment of partial and generalized seizures. Topiramate has been rarely associated with hepatic injury and largely when used in combination with other anticonvulsant medications.

JNJ-26990990 is a broad-spectrum anticonvulsant drug and a second-generation follow-up to the marketed drug topiramate. It offers the same anticonvulsant effects as topiramate but without the side effects associated with topiramate's carbonic anhydrase inhibition. Additionally, JNJ-26990990 has potential use in treating inflammatory pain, neuropathic pain, and depression. [It] entered phase II clinical trials in October 2007.